A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia-Reference-Cited by-同舟云学术

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

Published:2021-03 Issue:3 Volume:11 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Li Chunrui¹²^ORCID,Cao Wenyue¹²,Que Yimei¹²^ORCID,Wang Qiuxiang³,Xiao Yi¹²,Gu Chaojiang⁴⁵,Wang Di¹²,Wang Jue¹²,Jiang Lijun¹²,Xu Hao¹²,Xu Jinhuan¹²,Zhou Xiaoxi¹²,Hong Zhenya¹²,Wang Na¹²,Huang Liang¹²,Zhang Shangkun⁴⁵,Chen Liting¹²,Mao Xia¹²,Xiao Min¹²,Zhang Wei¹²,Meng Li¹²,Cao Yang¹²,Zhang Tongcun⁴⁵,Li Jian⁶,Zhou Jianfeng¹²

Affiliation:

1. Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China

2. Immunotherapy Research Center for Hematologic Diseases of Hubei Province Wuhan Hubei China

3. Wuhan No.1 Hospital Wuhan Hubei China

4. College of Life Science and Health Wuhan University of Science and Technology Wuhan Hubei China

5. Wuhan Bio‐Raid Biotechnology Co., Ltd. Wuhan Hubei China

6. Department of Hematology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject